key: cord-0699700-9u2rk376
authors: Rajarshi, Keshav; Chatterjee, Aroni; Ray, Shashikant
title: Combating COVID-19 with Mesenchymal Stem Cell therapy
date: 2020-05-14
journal: Biotechnol Rep (Amst)
DOI: 10.1016/j.btre.2020.e00467
sha: 0ceca0a9731522ddd6413ff56a0bb5c8b78fe1fd
doc_id: 699700
cord_uid: 9u2rk376

The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it’s initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.

The end of the year 2019 marked the beginning of a new challenge for humanity when several cases of severe respiratory ailments were reported in the city of Wuhan, Hubei province, China. The cases were earlier confused with regular flu and thought to be caused by the normal seasonal influenza virus. The accurate prognosis of the illness was very difficult to make in the beginning but was simulataneously identified to be a virus borne disesase. Due to the increasing severity in the following days, on January 1, the virus was declared novel.

Upon the complete phylogenetic analysis of the viral genome consisting of 29,903 nucleotides, it was found that this novel coronavirus had 89.1% similar nucleotides to a class of Severe Acute Respiratory Syndrome (SARS)like coronavirus. This novel virus belonged to the genus Betacoronavirus having the subgenus Sarbecovirus [1] . The novel coronavirus was earlier known to be found in Chinese bats [2] . WHO has assigned a brief name to the virus, SARS-CoV-2 and COVID-19 is the name assigned to the SARS-CoV-2 associated disease.

Till date no dedicated therapeutic or vaccination strategies have been implemented or confirmed to prevent COVID-19. Accessory therapeutic manueveurs including corticosteroid mediated inflammation reduction, convalescent plasma therapy, antibiotics for treatment of secondary bacterial sepsis and non-specific antivirals, etc., do not show much effectivity in severe cases of COVID-19. The main reason behind the failure of these therapies is the cytokine storm in the lungs generated by the virus. In the computed tomography scans, these cytokine storms (an augmented immune response in the body towards any external stimulus) appear as inflammatory lesions with ground-glass opacity [3, 4] . The commonly reported symptoms are cough, throat pain, mild/high fever, muscle soreness, or body ache. A sudden deterioration in the health condition of the patients are seen in the later stages of diseases progression. Rapid failure of multiple organs and ARDS (Acute Respiratory Distress Syndrome) results in death within a very short period of time. Cytokine storm has been indicated as the presumable causal factor for ARDS and multiple organ failure [5, 6] (Figure 1 ) .

WHO has approximated the case fatality rate (CFR) of COVID-19 as ranging from 0.3-1%, higher than that of influenza A which has a CFR of 0.1%. Various epidemiological studies conducted in countries implementing COVID-19 mitigation strategies has reported that around 80% of patients suffering from COVID-19 had symptomless or mild disease. 14% of the patients had severe ailments, and 6% of them were in critical condition [7] ( Figure 2 ) .

SARS-CoV-2 recognizes the angiotensin I converting enzyme 2 (ACE2) receptor by its spike glycoprotein (SARS-CoV-2S), which is a class I fusion protein. The virus is consecutively fused with the host cells. S1 subunit, via its receptor-binding domain, mediates the attachment of the spike protein. The protein changes its conformation after binding with the receptor. S2 domain of the spike protein is responsible for membrane fusion and internalization of the virus [8] . The host cell entry and spread are facilitated by priming of the spike protein of the virus by cellular transmembrane protease, serine 2 (TMPRSS2) [9] [10] [11] .

In the lungs, the ACE2 receptor and TMPRSS2 is commonly expressed in alveolar type II cells along with capillary endothelial cells. Therefore the characteristic symptom of SARS-CoV-2 infection is the severe respiratory ailment. This viral infection within the lungs results in a cytokine storm, thus elevating the level of many pro-inflammatory cytokines. The increased level of these cytokines leads to oedema, dysfunction in exchange of air, acute respiratory distress, and various other secondary infections, which may eventually cause death [9] [10] [11] [12] .

Presently, cell-based therapy, and above all, stem cell therapy has proven itself to be one of the most promising therapeutic approaches that provide opportunities to treat several diseases J o u r n a l P r e -p r o o f that were considered incurable earlier [13] . MSC therapy is preferred over other therapeutic strategies because they are free of ethical and social issues, they have a high proliferation rate and a low invasive nature. Mesenchymal cells can be obtained from various sources, including adipose tissues, dental pulp, bone marrow, umbilical cord, menstrual blood, fetal liver, and Bichat's fat pad.

MSCs can also be isolated from various adult tissues such as the infrapatellar fat pad, abdominal fat pad, and tissues associated with neonates such as placenta, Wharton's (gelatinous substance providing insulation and protection to the umbilical cord) jelly, cord blood, and amniotic fluid. These stem cells are multipotent (i.e., having several fates).

Storage of mesenchymal cells can be done so that they can be repetitively used for therapeutic purposes as they expand to volume in a suitable and short period of time. So far, the clinical trials of mesenchymal stem cells have not shown any unfavorable reaction towards the allogeneic MSCs. The efficacy and safety of the MSCs have been documented in many clinical trials very well [14] .

Remarkable reversal of severe COVID-19 symptoms even in critical condition were reported in two clinical studies conducted in China. These clinical studies discovered a novel therapeutic strategy as well as existing natural mechanism resisting acute inflammatory pneumonia.

A total of ten patients were taken as subjects, and the study was conducted on seven SARS-CoV-2 positive patients, out of which four of them showed severe symptoms, two showing common types of the syndrome, and one of them was critically ill. The other three patients with severe symptoms were enrolled for placebo control [9] . Clinical-grade human MSCs were intravenously administered to each of the seven patients. The patients were treated with 1 × 10 6 MSCs per kilogram body weight while their condition was worsening severely. They were observed for a total period of 14 days. Before the infusion of MSCs, all the patients had high fever (body temperatures ranging from 38.5°C to 39°C), reduced oxygen saturation, dyspnea (shortness of breath) and pneumonia. The study showed that almost all the symptoms displayed by the patients before infusion, subsided under 2-4 days after they received the infusion. The oxygen saturation, with or without oxygen uptake (approximately 5 liters/minute), rose to ≥ 95% at rest. The profile of the immune system constitution was Another study involved a critically ill ventilator ridden COVID-19 patient who was administered with human umbilical cord MSC (hUCMSC). This patient was treated with 3 infusions of 5 × 10 7 hUCMSC at the interval of 3 days, and the patient was able to walk within 4 days of her second cell infusion. The essential parameters like T-cell counts were restored back to normal levels. The patient displayed no observable side effects [15] . 

COVID-19 triggers an exaggerated immune reaction in the body by producing large amounts of various inflammatory factors including several cytokines, chemokines and immune reactive cells. It can be hypothesized that the MSC therapy might prevent the triggering of cytokine storm by the activated immune system, and the reparative properties of the stem cells might promote endogenous repair [18] . Mesenchymal stem cells when intravenously injected will lead to some part of the population getting entrapped in the lungs. While trapped within the lungs, a wide variety of soluble mediators, including antimicrobial peptides, antiinflammatory cytokines, extracellular vesicles, and angiogenic growth factors are released by the MSCs [19] [20] [21] . The pattern of anti-inflammatory mediators released is specific for the inflammatory lung environment encountered. The pattern of these released mediators are regulated through differential activation of the damage and pathogen-associated molecular pathogen receptors expressed on the cell surfaces of MSCs, [22] including TLRs (toll-like J o u r n a l P r e -p r o o f receptors) that, in case of COVID-19, are activated by viral unmethylated CpF-DNA (TLR9) and viral RNA (TLR3), leading to sub sequential cellular signalling pathways and thereafter activation of MSCs [23] . Keratinocyte Growth Factor (KGF) and angiopoietin-1 (Ang-1) secreted by MSCs promote the restoration of disrupted alveolar-capillary barriers due to the pathogenesis of ARDS [24] . Extracellular vesicles containing specific miRNA ans inhibitory mRNAs are also known to regulate the protective effects of MSCs in pre-clinical models of non-infectious acute lung inhuries or bacterial sepsis in lungs [25] . The pulmonary microenvironment could be recovered with the help of these MSCs, thus protecting the alveolar epithelial cells. Hence, pulmonary fibrosis of the lungs could be prevented, which may lead to curing COVID-19 caused pneumonia. In the multiple disease condition, the immunomodulatory effects will be responsible for improved function after MSC infusion. A variety of paracrine factors are secreted by these cells. These paracrine factors interact with the immune cells, eventually leading to immunomodulation. The vigorous anti-inflammatory activities of MSCs will actually be responsible for improvements after their infusion in COVID-19 patients.

It has been found that after infusion of MSCs in COVID-19 patients, the number of peripheral lymphocytes increased while the levels of C-reactive protein (CRP) decreased. The overactivated cytokine-secreting immune cells dwindled within 6 days in the circulating blood. Furthermore, after the MSC treatment, the population of regulatory dendritic cells (CD14 + CD11b mid ) increased. A major pro-inflammatory cytokine, TNF-α (Tumour Necrosis Factor), exhibited a decline in its levels in the MSC treated COVID-19 patients, with an elevation in the concentration of IL-10 (Interleukin-10) compared to the patients treated with conventional therapy [9] . Table 1 

The authors report no conflicts of interest.

A new coronavirus associated with human respiratory disease in China

Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats

Mesenchymal stem cells and management of COVID-19 pneumonia

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

How will countrybased mitigation measures influence the course of the COVID-19 epidemic pp

Targeting SARS-CoV-2 Spike Protein of COVID-19 with Naturally Occurring Phytochemicals: An in Silco Study for Drug Development

Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

Biological Products: Cellular Therapy and FDA Approved Products, Stem cell reviews and reports

The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review, Current stem cell research & therapy

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial, The Lancet Respiratory medicine

Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy

Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinflammatory protein TSG-6

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

Mesenchymal Stem Cell Microvesicles Restore Protein Permeability Across Primary Cultures of Injured Human Lung Microvascular Endothelial Cells, Stem cells translational medicine

Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling

A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype

Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria, American journal of respiratory and critical care medicine

Therapeutic Effects of Human Mesenchymal Stem Cellderived Microvesicles in Severe Pneumonia in Mice, American journal of respiratory and critical care medicine

KR and SR thanks IIEST Shibpur and Mahatma Gandhi Central University Motihari, Bihar, respectively.J o u r n a l P r e -p r o o f